DiaSorin announced that it has completed studies in Italy for its COVID-19 test to support the product’s launch there.

The diagnostic identifies antibodies against the novel coronavirus and can diagnose patients who have already been infected and have recovered.

The company hopes to receive both CE mark certification and the FDA’s Emergency Use Authorization by the end of the month.